Shilpa Medicare receives GMP certification from SFDA for Unit VI facility

10 Jul 2025 Evaluate

Shilpa Medicare has received GMP certification from Saudi Food and Drug Authority (SFDA), Saudi Arabia, for its Unit VI facility, located at Dabaspet, Bengaluru. This follows the on-site inspection of this site from February 18 to February 20, 2025, which was closed with ZERO observations. This was a full GMP inspection of entire facility with specific focus on Ondansetron Oral Film drug product.

This facility of the company is engaged in the manufacture, testing, storage and release of finished dosage forms in the category of Oral Films and Transdermal Patches. Oral Films are currently being supplied from this site to US, Australia and other Emerging countries. The site is approved by European Medicine Agency, Europe following a recent inspection by Finnish regulators.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.


Shilpa Medicare Share Price

323.80 -7.40 (-2.23%)
15-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.25
Dr. Reddys Lab 1280.40
Cipla 1507.25
Zydus Lifesciences 921.25
Lupin 2090.15
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×